Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Assessment of Concurrent Administration of JE SA 14-14-2 and Measles Vaccines
NCT00412516Phase 3Completed
- Sponsor
- PATH
- Start
- Dec 2006
- Primary completion
- Mar 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of japanese encephalitis vaccine sa14-14-2 in Japanese encephalitis (JE) and measles (3 arms), sponsored by PATH. Primary endpoint: Measles Seropositivity at 36 months. Started Dec 2006; status: completed.
02
Drugs
japanese encephalitis vaccine sa14-14-2
03
Conditions
Japanese encephalitis (JE)measles
Beyond the preview
Go deeper on NCT00412516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00412516.